15 min

The Aducanumab Aftermath: The Payer Tradeoffs

    • News

A controversial new $56,000 Alzheimer’s drug could wreak financial havoc on insurers, seniors and taxpayers.
This episode is part of a special weeklong series examining the potentially sweeping consequences this drug, known as aducanumab, could have on millions of patients’ lives and billions of dollars in health care spending.
Guest:
Mark Miller, PhD, Executive Vice President for Health Care, Arnold Ventures
Explore the full series and additional resources: https://tradeoffs.org/aducanumab
Read a transcript of this episode: https://tradeoffs.org/2021/06/24/the-aducanumab-aftermath-the-payer/
Sign up for our weekly newsletter to see what research health policy experts are reading right now, plus recommendations from our staff: bit.ly/tradeoffsnewsletter
Support this type of journalism today, with a gift: https://tradeoffs.org/donate
Follow us on Twitter: https://twitter.com/tradeoffspod

See acast.com/privacy for privacy and opt-out information.

A controversial new $56,000 Alzheimer’s drug could wreak financial havoc on insurers, seniors and taxpayers.
This episode is part of a special weeklong series examining the potentially sweeping consequences this drug, known as aducanumab, could have on millions of patients’ lives and billions of dollars in health care spending.
Guest:
Mark Miller, PhD, Executive Vice President for Health Care, Arnold Ventures
Explore the full series and additional resources: https://tradeoffs.org/aducanumab
Read a transcript of this episode: https://tradeoffs.org/2021/06/24/the-aducanumab-aftermath-the-payer/
Sign up for our weekly newsletter to see what research health policy experts are reading right now, plus recommendations from our staff: bit.ly/tradeoffsnewsletter
Support this type of journalism today, with a gift: https://tradeoffs.org/donate
Follow us on Twitter: https://twitter.com/tradeoffspod

See acast.com/privacy for privacy and opt-out information.

15 min

Top Podcasts In News